Subscribe to RSS
DOI: 10.1055/s-0031-1297164
Pediatric Hemophilia: A Review
Publication History
Publication Date:
20 December 2011 (online)

ABSTRACT
The hemophilias are the most common X-linked inherited bleeding disorders, which if not properly managed can lead to chronic disease and lifelong disabilities. The challenges and issues in newborns are different from that in older children and adults. Bleeding events still predominate as the diagnostic trigger in children, however, the sites of bleeding vary with age. While delivery-associated intracranial hemorrhage (ICH), circumcision, and venipuncture bleeding are common in the newborn period, joint disease and head trauma occur in the older child and adolescent. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitors and ICH are the most challenging complications and prophylaxis is emerging as the optimal preventive care strategy.
KEYWORDS
Hemophilia - inhibitor - prophylaxis - intracranial hemorrhage - central venous access devices - newborns - pediatrics
REFERENCES
- 1
Soucie J M, Evatt B, Jackson D. The Hemophilia Surveillance System Project Investigators .
Occurrence of hemophilia in the United States.
Am J Hematol.
1998;
59
(4)
288-294
MissingFormLabel
- 2
Tagariello G, Iorio A, Santagostino E Italian Association Hemophilia Centre (AICE) et al.
Comparison of the rates of joint arthroplasty in patients with severe factor VIII
and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.
Blood.
2009;
114
(4)
779-784
MissingFormLabel
- 3
Soucie J M, McAlister S, McClellan A, Oakley M, Su Y.
The universal data collection surveillance system for rare bleeding disorders.
Am J Prev Med.
2010;
38
(4, Suppl)
S475-S481
MissingFormLabel
- 4
Kulkarni R, Soucie J M, Lusher J Haemophilia Treatment Center Network Investigators et al.
Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies
with haemophilia diagnosed before the age of 2 years: a report from The Centers for
Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project.
Haemophilia.
2009;
15
(6)
1281-1290
MissingFormLabel
- 5 World Federation of Hemophilia Report on the Annual Global Survey 2009. March 2011. Available at http://www.wfh.org/2/docs/Publications/Statistics/2009_Global_Survey_Report.pdf Accessed Oct 1, 2011
MissingFormLabel
- 6
Evatt B L.
The tragic history of AIDS in the hemophilia population, 1982-1984.
J Thromb Haemost.
2006;
4
(11)
2295-2301
MissingFormLabel
- 7
Trimble S R, Parker C S, Grant A M, Soucie J M, Reyes N.
Assessing emerging infectious threats to blood safety for the blood disorders community.
Am J Prev Med.
2010;
38
(4, Suppl)
S468-S474
MissingFormLabel
- 8
Oldenburg J.
Mutation profiling in haemophilia A.
Thromb Haemost.
2001;
85
(4)
577-579
MissingFormLabel
- 9
Bolton-Maggs P H, Pasi K J.
Haemophilias A and B.
Lancet.
2003;
361
(9371)
1801-1809
MissingFormLabel
- 10
Monroe D M, Hoffman M.
What does it take to make the perfect clot?.
Arterioscler Thromb Vasc Biol.
2006;
26
(1)
41-48
MissingFormLabel
- 11
Baehner R L, Strauss H S.
Hemophilia in the first year of life.
N Engl J Med.
1966;
275
(10)
524-528
MissingFormLabel
- 12
Chalmers E A.
Haemophilia and the newborn.
Blood Rev.
2004;
18
(2)
85-92
MissingFormLabel
- 13
Kenet G, Chan AKC, Soucie J M, Kulkarni R.
Bleeding disorders in neonates.
Haemophilia.
2010;
16
(Suppl 5)
168-175
MissingFormLabel
- 14
Kulkarni R, Lusher J.
Perinatal management of newborns with haemophilia.
Br J Haematol.
2001;
112
(2)
264-274
MissingFormLabel
- 15
Rodriguez V, Titapiwatanakun R, Moir C, Schmidt K A, Pruthi R K.
To circumcise or not to circumcise? Circumcision in patients with bleeding disorders.
Haemophilia.
2010;
16
(2)
272-276
MissingFormLabel
- 16
Pollmann H, Richter H, Ringkamp H, Jürgens H.
When are children diagnosed as having severe haemophilia and when do they start to
bleed? A 10-year single-centre PUP study.
Eur J Pediatr.
1999;
158
(Suppl 3)
S166-S170
MissingFormLabel
- 17
Valentino L A.
Blood-induced joint disease: the pathophysiology of hemophilic arthropathy.
J Thromb Haemost.
2010;
8
(9)
1895-1902
MissingFormLabel
- 18
Manco-Johnson M J, Abshire T C, Shapiro A D et al..
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe
hemophilia.
N Engl J Med.
2007;
357
(6)
535-544
MissingFormLabel
- 19
Soucie J M, Cianfrini C, Janco R L et al..
Joint range-of-motion limitations among young males with hemophilia: prevalence and
risk factors.
Blood.
2004;
103
(7)
2467-2473
MissingFormLabel
- 20
Beyer R, Ingerslev J, Sørensen B.
Current practice in the management of muscle haematomas in patients with severe haemophilia.
Haemophilia.
2010;
16
(6)
926-931
MissingFormLabel
- 21
Nuss R, Soucie J M, Evatt B. Hemophilia Surveillance System Project Investigators .
Changes in the occurrence of and risk factors for hemophilia-associated intracranial
hemorrhage.
Am J Hematol.
2001;
68
(1)
37-42
MissingFormLabel
- 22
Stieltjes N, Calvez T, Demiguel V French ICH Study Group et al.
Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation,
management and prognosis factors for death.
Haemophilia.
2005;
11
(5)
452-458
MissingFormLabel
- 23
Ljung R C.
Intracranial haemorrhage in haemophilia A and B.
Br J Haematol.
2008;
140
(4)
378-384
MissingFormLabel
- 24
Kulkarni R, Lusher J M.
Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of
the literature.
J Pediatr Hematol Oncol.
1999;
21
(4)
289-295
MissingFormLabel
- 25
Gupta S N, Kechli A M, Kanamalla U S.
Intracranial hemorrhage in term newborns: management and outcomes.
Pediatr Neurol.
2009;
40
(1)
1-12
MissingFormLabel
- 26
Nakar C, Cooper D L, DiMichele D.
Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage
in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia
and Thrombosis Research Society Registry (2004-2008).
Haemophilia.
2010;
16
(4)
625-631
MissingFormLabel
- 27
Ljung R.
The optimal mode of delivery for the haemophilia carrier expecting an affected infant
is vaginal delivery.
Haemophilia.
2010;
16
(3)
415-419
MissingFormLabel
- 28
James A H, Hoots K.
The optimal mode of delivery for the haemophilia carrier expecting an affected infant
is caesarean delivery.
Haemophilia.
2010;
16
(3)
420-424
MissingFormLabel
- 29
Looney C B, Smith J K, Merck L H et al..
Intracranial hemorrhage in asymptomatic neonates: prevalence on MR images and relationship
to obstetric and neonatal risk factors.
Radiology.
2007;
242
(2)
535-541
MissingFormLabel
- 30
Smith A R, Leonard N, Kurth M H.
Intracranial hemorrhage in newborns with hemophilia: the role of screening radiologic
studies in the first 7 days of life.
J Pediatr Hematol Oncol.
2008;
30
(1)
81-84
MissingFormLabel
- 31
Wilson D A, Nelson Jr M D, Fenstermacher M J The Hemophilia Growth and Development Study Group et al.
Brain abnormalities in male children and adolescents with hemophilia: detection with
MR imaging.
Radiology.
1992;
185
(2)
553-558
MissingFormLabel
- 32
Nelson Jr M D, Maeder M A, Usner D et al..
Prevalence and incidence of intracranial haemorrhage in a population of children with
haemophilia. The Hemophilia Growth and Development Study.
Haemophilia.
1999;
5
(5)
306-312
MissingFormLabel
- 33
Eyster M E, Gill F M, Blatt P M, Hilgartner M W, Ballard J O, Kinney T R.
Central nervous system bleeding in hemophiliacs.
Blood.
1978;
51
(6)
1179-1188
MissingFormLabel
- 34
Gouw S C, van der Bom J G, Marijke van den Berg H.
Treatment-related risk factors of inhibitor development in previously untreated patients
with hemophilia A: the CANAL cohort study.
Blood.
2007;
109
(11)
4648-4654
MissingFormLabel
- 35
Chambost H.
Assessing risk factors: prevention of inhibitors in haemophilia.
Haemophilia.
2010;
16
(Suppl 2)
10-15
MissingFormLabel
- 36
Kempton C L, White II G C.
How we treat a hemophilia A patient with a factor VIII inhibitor.
Blood.
2009;
113
(1)
11-17
MissingFormLabel
- 37
Verbruggen B, van Heerde W L, Laros-van Gorkom B A.
Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen.
Semin Thromb Hemost.
2009;
35
(8)
752-759
MissingFormLabel
- 38
Chitlur M, Warrier I, Rajpurkar M, Lusher J M.
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor
registry (1997-2006).
Haemophilia.
2009;
15
(5)
1027-1031
MissingFormLabel
- 39 DiMichele D. Inhibitors to factor VIII/IX: immune tolerance. In: Lee C, Berntorp E, Hoots K, eds. Textbook of Hemophilia. UK: Wiley-Blackwell; 2010: 66-74
MissingFormLabel
- 40
Valentino L A, Kawji M, Grygotis M.
Venous access in the management of hemophilia.
Blood Rev.
2011;
25
(1)
11-15
MissingFormLabel
- 41
Usner D W, Donfield S M, Sirois P A, Gomperts E D, Bale Jr J F, Mitchell W G.
Hemophilia morbidity, cognitive functioning, and academic achievement.
J Pediatr.
1998;
133
(6)
782-787
MissingFormLabel
- 42
Shapiro A D, Donfield S M, Lynn H S Academic Achievement in Children with Hemophilia Study Group et al.
Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia
Study.
Pediatrics.
2001;
108
(6)
E105
MissingFormLabel
- 43
Spencer M L, Wodrich D L, Schultz W, Wagner L, Recht M.
Inattention, hyperactivity-impulsivity, academic skills and psychopathology in boys
with and without haemophilia.
Haemophilia.
2009;
15
(3)
701-706
MissingFormLabel
- 44
Bladen M, Khair K, Liesner R, Main E.
Long-term consequences of intracranial haemorrhage in children with haemophilia.
Haemophilia.
2009;
15
(1)
184-192
MissingFormLabel
- 45 MASAC recommendations concerning products licensed for the treatment of hemophilia
and other bleeding disorders. MASAC document #195. 2010. The National. New York: National Hemophilia Foundation 116 West 32nd Street, New York,
NY 10001 [Available at http://www.hemophilia.org]
MissingFormLabel
- 46
Batorova A, Martinowitz U.
Continuous infusion of coagulation factors: current opinion.
Curr Opin Hematol.
2006;
13
(5)
308-315
MissingFormLabel
- 47
Morfini M.
Secondary prophylaxis with factor IX concentrates: continuous infusion.
Blood Transfus.
2008;
6
(Suppl 2)
s21-s25
MissingFormLabel
- 48 Kulkarni R, Chitlur M, Lusher J. Treatment of congenital coagulopathies. In: Mintz P D, ed. Transfusion Therapy: Clinical Principles and Practice. 3rd ed. Bethesda, MD: AABB Press; 2011: 167-208
MissingFormLabel
- 49
Feldman B M, Pai M, Rivard G E Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group et al.
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years
of the Canadian Hemophilia Primary Prophylaxis Study.
J Thromb Haemost.
2006;
4
(6)
1228-1236
MissingFormLabel
- 50
Ljung R.
Prophylactic therapy in haemophilia.
Blood Rev.
2009;
23
(6)
267-274
MissingFormLabel
- 51
Auerswald G, Bidlingmaier C, Kurnik K.
Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals
is still effective in minimizing FVIII inhibitor developments in previously untreated
patients—long-term follow-up and continuing experience. Haemophilia.
2011 [Epub ahead of print]
MissingFormLabel
Roshni KulkarniM.D.
Professor and Director, Pediatric & Adolescent Hematology/Oncology; Director (Pediatrics),
MSU Centers for Bleeding and Clotting Disorders; Former Director and Distinguished
Hematology Consultant, Division of Blood Disorders
CDC, B 216 Clinical Center; Department of Pediatrics and Human Development, Michigan
State University, East Lansing, MI 48824
Email: Roshni.Kulkarni@hc.msu.edu
Email: Roshni@msu.edu